| Name | Title | Contact Details |
|---|
Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead`s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.
Dendreon is a biotechnology company with a singular mission: to harness the power of the body`s immune system to safely improve and extend the lives of people battling cancer. Dendreon`s PROVENGE® (sipuleucel-T), which was approved by the U.S. Food and Drug Administration in April 2010, is the only cellular immunotherapy cancer treatment available. Dendreon is working to expand the application of its technology to discover, develop, manufacture and market additional product candidates for a variety of cancers in the future. Dendreon headquarters are in in Seal Beach, California.
Ibidi is a Verona, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company`s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio`s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.